Author

K. Hwang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

T. Sim· 2 shared C. K. Min· 1 shared C. Seo· 1 shared D. Jang· 1 shared E. Jeon· 1 shared H.-S. Choi· 1 shared I. You· 1 shared J. Bae· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

T. Sim

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeted Degradation of METTL3 Against Acute Myeloid Leukemia and Gastric Cancer.

K. Hwang, J. Bae, Y.-L. Jhe, J. Kim, J.-H. Cheong, T. Sim

This study develops KH12, a METTL3 degrader, showing potent anti-leukemia and anti-gastric cancer effects through m6A-dependent and -independent mechanisms.

bioRxiv · Feb 2, 2024Biochemistry

Targeted Kinase Degradation via the KLHDC2 Ubiquitin E3 Ligase

Y. Kim, C. Seo, E. Jeon, I. You, K. Hwang, N. Kim, H.-S. Choi, S. M. Hinshaw, T. Sim, N. Gray

This study demonstrates the use of KLHDC2 as a substrate adaptor for targeted protein degradation using peptide-based bivalent compounds.

bioRxiv · Dec 17, 2022Biochemistry

GV1001 prevents ovarian follicle loss triggered by an anti-VEGF monoclonal antibody targeting non-small cell lung carcinoma xenografts in mice

D. Jang, M. Kim, C. K. Min, J. Lee, Y.-J. Jang, K. Hwang

This study shows that GV1001 reduces ovarian follicle loss caused by bevacizumab in mice without affecting its anti-cancer effects.

bioRxiv · Jul 30, 2019 · PreprintPharmacology & Toxicology